Kirkpatrick B. Fergus

Abstract The Women Informed to Screen Depending on Measures of risk (WISDOM) Study (clinicaltrials.gov NCT02620852, 2016-08-31) is pragmatic randomized controlled trial evaluating risk assessment to inform the age to start, frequency and modality of breast cancer screening and risk reduction. The WISDOM Study uses a preference-tolerant design, enabling women who decline randomization to self-select their screening arm.

Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial Supplement 1. Supplement 2. Trial Protocol Change Log Supplement 3. eTable 1. Abbreviated Baseline Survey Family History of Breast/Ovarian Cancer eTable 2. Demographic Characteristics of Participants With Pathogenic Variants in 5 BC Risk Genes eTable 3. Composite Family History Risk of Breast Cancer According to Germline Test Results eTable 4.

To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Figure 1 Distribution of Sexual Health Inventory for Men (SHIM) and Female Sexual Function Index (FSFI) scores according to age group. A, Distribution of SHIM scores according to age category in our sample. The cutoff for erectile dysfunction (ED) is a score of 21, indicated by the horizontal line.